View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Eyenovia Provides Development Update on Optejet User Filled Device (UF...

Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is designed to work with a...

 PRESS RELEASE

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Me...

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing an...

 PRESS RELEASE

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirem...

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low...

Golub Capital BDC, Inc.: Key facts and statistics - fiscal 2024

A summary company profile, detailing Golub Capital BDC, Inc.’s business operations and financial highlights.

 PRESS RELEASE

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Sen...

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered in...

 PRESS RELEASE

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dis...

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including difficul...

 PRESS RELEASE

Eyenovia Announces 1-for-80 Reverse Stock Split

Eyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that its Board of Directors approved a 1-for-80 reverse stock split (the “Reverse Sto...

Moody's Ratings upgrades Golub Capital BDC, Inc.'s senior unsecured ra...

Moody's Ratings (Moody's) has upgraded the long-term issuer and senior unsecured ratings of Golub Capital BDC, Inc. (GBDC) to Baa2 from Baa3. We also upgraded GBDC's senior unsecured shelf rating to (P)Baa2 from (P)Baa3. Following the upgrade, the outlook was changed to stable from positive. RATIN...

 PRESS RELEASE

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, ...

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company, today announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“...

 PRESS RELEASE

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternativ...

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 10, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 7, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Off...

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”),  an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warran...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 30, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Off...

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrant...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 23, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eyenovia Provides Update on Restructuring Efforts

Eyenovia Provides Update on Restructuring Efforts Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize stakeholder value NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue Capital Management L.P. has agreed to support a potential restructuring of Eyenovia’s Loan a...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch